| Objective: In this paper, different doses of tirofiban in elderly diabetic patients withacute myocardial infarction (DM-AMI) PCI therapeutic applications of value and safety of apreliminary study and discussion.Methods: Our hospital with acute myocardial infarction (DM-AMI), were randomlydivided into group A, group B and group C were treated from November2011to September2013period of180elderly patients with diabetes, all60patients in each group cases. A groupwas given aspirin plus clopidogrel, aspirin plus clopidogrel group B on the basis of low-dosetirofiban therapy, group C on the basis of aspirin+clopidogrel+conventional dose tirofibantreatment, the three groups after both subcutaneous low molecular weight heparin in4-5days,after conventional aspirin100mg, clopidogrel75mg and applications based on individualdifferences in secondary prevention of coronary heart disease drugs. Observed duringhospitalization and follow-up three months major adverse cardiovascular events (nonfatalmyocardial infarction, angina pectoris, myocardial infarction) and the incidence of bleedingevents; compare before PCI, coronary TIMI flow grade.Results: The group B and group C patients before and after treatment was significantlybetter than TIMI grade improvement in group A patients (P <0.05); Group B patients withbleeding event rate was significantly lower than that in group C patients, the difference wassignificant (P <0.05); B, group C patients with cardiovascular incidence of adverse eventswas not significant (P>0.05). Conclusions: Tirofiban in elderly diabetic patients with acute myocardial infarction PCIclinical effects of treatment was significantly and effectively improve the therapeutic effect, itis worth promoting. |
PDF Full Text Request